WHO Issues First-Ever Global Guideline for GLP-1 Medications in Treating Obesity, And It Confirms What Medi-Weightloss Has Practiced for 20 Years
This week, the World Health Organization (WHO) released its first global guideline recommending long-term use of GLP-1 medications as part of a comprehensive treatment plan for adults with obesity. WHO’s statement underscores a critical truth:
➡️ Obesity is a chronic, relapsing disease, not a matter of willpower.
➡️ Medication alone is not enough. Effective care must pair medical therapy with personalized nutrition, physical activity guidance, behavioral support, and ongoing monitoring.
At Medi-Weightloss, we couldn’t agree more. For 20 years, our nationally recognized, medically-supervised program has been built on this very approach:
✔️ Comprehensive medical evaluation
✔️ Evidence-based behavioral and nutrition counseling
✔️ Personalized care plans
✔️ Access to a full range of weight loss medications, including GLP-1s
✔️ Weekly accountability and long-term support
Obesity care is entering a new era. We’re proud to continue leading the way with a science-driven, patient-centered model that mirrors the gold standard the WHO recommends.